When it comes to migraine treatment,
Choose UBRELVY® for a migraine treatment that is rapid, powerful, and proven1,2
Explore how UBRELVY can help patients manage migraine pain.
RAPID
Quick pain relief1
POWERFUL
Zero pain, sustained1,2
PROVEN
Well established in market2
About 40% of patients achieved pain relief at 1 hour—and more than 60% at 2 hours1-3
Secondary endpoint: Pain relief at 2 hours with a single dose1-3*
Limitation: The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity. Results could represent chance findings.
HELP PATIENTS QUICKLY ACHIEVE MIGRAINE PAIN RELIEF1
Limitation: The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity.
*Pain relief was defined as a reduction in migraine pain from moderate or severe to mild or none postdose.1
†UBRELVY 100 mg was included only in ACHIEVE I.1
UBRELVY is an
immediate-release tablet that
is rapidly dissolved and
pharmacologically active
within minutes2-4
POWERFUL
ZERO MIGRAINE PAIN, SUSTAINED
Just one dose of UBRELVY delivered zero migraine pain for the majority of patients at Hours 4 and 82
Co-primary endpoint:
- Single-dose pain freedom at 2 hours without rescue medication1,2,4*
- At 2 hours, 21% of patients taking UBRELVY 50 mg (182/886) or 100 mg (95/448) were completely pain-free vs 13% (119/912) taking placebo2
ZERO MIGRAINE PAIN SUSTAINED FROM 2 HOURS THROUGH 24 AND 48 HOURS1,2§
Secondary endpoint: sustained pain freedom from 2 to 24 hours‖
Of patients who achieved pain freedom at Hour 2 (50 mg; 182/886 and 100 mg; 95/448)2:
- At 24 hours: 70% (50 mg; 119/171) and 77% (100 mg; 68/88) sustained zero migraine pain2
- At 48 hours: 60% (50 mg; 96/159) and 72% (100 mg; 62/86) sustained zero migraine pain2§
Across clinical trials:
- 14% of patients treated with UBRELVY 50 mg (vs 8% with placebo) and 15% of those taking UBRELVY 100 mg (vs 9% with placebo) achieved pain freedom at 2 hours and remained pain-free at 24 hours1
Limitation: The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity. Results could represent chance findings.
*Pain freedom was defined as a reduction from moderate/severe headache pain to no pain.1 Pain freedom over time was an additional efficacy endpoint. Data collected after rescue medication or second dose was excluded.2
†UBRELVY 100 mg was included only in ACHIEVE I.1
§Pain freedom at 48 hours was a secondary (EU only) endpoint.2
‖Sustained pain freedom from 2 to 24 hours was defined as pain freedom with no administration of either rescue medication or second dose of investigational product, and with no occurrence thereafter of mild, moderate, or severe headache pain during the relevant number of hours after dosing.6
UBRELVY IS THE ONLY GEPANT WITH AN OPTIONAL SECOND DOSE1,6*
Migraine attacks can be unpredictable; no two attacks are the same7
In a substudy of patients who took an optional second dose of UBRELVY 50 mg after 2 hours of pain relief: 55% (50 mg: 41/75) achieved pain freedom with the second dose (41/75) vs 33% (19/57) with placebo8†
*A second dose may be taken at least 2 hours after the initial dose. The maximum dose in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period has not been established.1
†Patients who received an initial dose of UBRELVY and requested an optional second dose 2 to 48 hours after the initial dose were re-randomized to either receive placebo or repeat their previous dose of UBRELVY.8,9
Impact of UBRELVY
UBRELVY studies included a diverse patient population.1,2 It may be appropriate for patients you’re already seeing in your practice.
RETURN TO FUNCTION
A majority of patients achieved normal function at 2, 4, and 8 hours2
Additional endpoint: Percentage of patients achieving normal function* at 2, 4, and 8 hours with a single dose2†
Limitation: The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity. Results could represent chance findings.
UBRELVY HELPED THE MAJORITY OF PATIENTS GET BACK TO NORMAL FUNCTION2
- At 2 hours, 64% (100 mg; 125/196) and 60% (50 mg; 228/383) of patients taking UBRELVY achieved normal function compared with 54% (139/258) taking placebo2
- At 4 hours, 81% (100 mg; 158/196) and 77% (50 mg; 295/383) of patients taking UBRELVY achieved normal function compared with 67% (172/258) taking placebo2
- At 8 hours, 91% (100 mg; 179/196) and 87% (50 mg; 334/384) of patients taking UBRELVY achieved normal function compared with 76% (195/258) taking placebo2
Limitation: The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity.
*Patients were asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely
impaired, cannot do all or most things, bed rest may be necessary).2
†Data collected after rescue medication or second dose was excluded.2
‡UBRELVY 100 mg was included only in ACHIEVE I.1
UBRELVY works differently
UBRELVY is the first acute treatment for migraine to directly block calcitonin gene-related peptide (CGRP).6
PROVEN
Well established in market
UBRELVY CONTINUES TO BE THE MOST PRESCRIBED BRANDED TREATMENT FOR MIGRAINE ATTACKS1,10
Since approval, UBRELVY is most prescribed in its class11
As of 10/22.
Every patient is different—UBRELVY studies included a diverse patient population,
including those with1,2:
Every patient is
different—UBRELVY studies
included a diverse patient
population, including those
with1,2:
PRIOR
TRIPTAN USE
CONCOMITANT
PREVENTIVE USE
HISTORY OF
DEPRESSION
HISTORY OF
ANXIETY
CARDIOVASCULAR
RISK
Up next: Learn about the
safety of UBRELVY